Manufacturing of Azithromycin 250 MG Tablets (6-count bottle)

The contract mandates the full-scale manufacturing of azithromycin 250 mg tablets in compliance with FDA standards, covering every stage from formulation and production to packaging in 6-count bottles, labeling, and stringent quality control protocols. All activities must adhere to current good manufacturing practices and ensure product integrity, potency, and safety for end-use by U.S. military and related health services under the Department of Defense. The work is structured as a subcontract under NAICS code 325412, with a submission deadline of June 16, 2026, and is being managed by DLA Troop Support as part of a broader defense healthcare logistics initiative. Production must be scalable and consistent, with documentation and traceability maintained throughout the lifecycle to meet federal regulatory and audit requirements.